Page last updated: 2024-11-07

o(6)-benzyl-2'-deoxyguanosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID125392
CHEMBL ID244316
SCHEMBL ID6016114
MeSH IDM0234541

Synonyms (12)

Synonym
o6-b-dg
CHEMBL244316
(2r,3s,5r)-5-(2-amino-6-phenylmethoxypurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
129732-90-7
o(6)-benzyl-2'-deoxyguanosine
guanosine, 2'-deoxy-6-o-(phenylmethyl)-
o6-benzyl-2'-deoxyguanosine
SCHEMBL6016114
DTXSID00926478
6-(benzyloxy)-9-(2-deoxypentofuranosyl)-3,9-dihydro-2h-purin-2-imine
(2r,3s,5r)-5-(2-amino-6-(benzyloxy)-9h-purin-9-yl)-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2r,3s,5r)-5-[2-amino-6-(benzyloxy)-9h-purin-9-yl]-2-(hydroxymethyl)oxolan-3-ol

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Groups treated with regional temozolomide alone (350 mg/kg), systemic temozolomide with O6BG, or vehicle combined with O6BG showed no significant tumor responses compared with controls."( Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine.
Abdel-Wahab, OI; Abdel-Wahab, Z; Augustine, C; Cheng, TY; Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T; Yoshimoto, Y, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" With additional dosage adjustments, we found that tumor suppression of >90 days without toxicity was observed at 200 mg/m2 dBG and 23 mg/m2 BCNU."( Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis, DM; Moschel, RC; Pegg, AE; Schold, SC, 1999
)
0.3
" A dose-response relationship was determined between the BG dose and the percentage of subjects with undetectable AGT."( O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas.
Berger, MS; Chang, SM; Davis, RL; Fink, KL; Hess, KR; Kokkinakis, DM; Mehta, MP; Prados, MD; Robins, HI; Schiff, D; Schold, SC, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Methylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)ED501.25000.02000.63004.7000AID32854; AID32856
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
DNA ligationMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
DNA alkylation repairMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
methylationMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
negative regulation of apoptotic processMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
positive regulation of double-strand break repairMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
DNA repairMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
DNA bindingMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
methyltransferase activityMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
DNA-methyltransferase activityMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
metal ion bindingMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
methylated-DNA-[protein]-cysteine S-methyltransferase activityMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleoplasmMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
membraneMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
nucleusMethylated-DNA--protein-cysteine methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID32854In vitro inhibition of human alkyl transferase in HT-29 cell-free extracts.1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase.
AID298496Inactivation of human alkyltransferase in presence of DNA2007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.
AID32856Inhibitory activity against alkyl transferase in HT-29 cells1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase.
AID298495Inactivation of human alkyltransferase in absence of DNA2007Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (23.53)18.2507
2000's12 (70.59)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.56 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (5.26%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]